← Back to Clinical Trials
Recruiting NCT06485895

NCT06485895 Clinical Evaluation of an IGRA Test for the Diagnosis of Active and Latent Tuberculosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06485895
Status Recruiting
Phase
Sponsor Assistance Publique Hopitaux De Marseille
Condition TUBERCULOSIS
Study Type INTERVENTIONAL
Enrollment 500 participants
Start Date 2024-07-30
Primary Completion 2027-07-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
test IGRATEST QUATIFERON TB Gold Plus

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 500 participants in total. It began in 2024-07-30 with a primary completion date of 2027-07-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Methodology This is a single-center study carried out as part of routine patient care. The aim of the study is to determine the performance of the 2nd generation TB-IGRA test in the diagnosis of tuberculosis.

Eligibility Criteria

Inclusion Criteria: * Individual at least 18 years of age * Patient presenting for treatment of tuberculosis disease * Having undergone or benefiting from screening for tuberculosis using a medically prescribed reference IGRA test. * Informed patient who has not expressed opposition to participating in the study. French-speaking patient with unambiguous understanding of oral and written instructions. Exclusion Criteria: Persons in a period of exclusion from another study * Pregnant, parturient or breast-feeding women; * Person deprived of liberty by judicial or administrative decision

Contact & Investigator

Central Contact

PR PIERRE EDOUARD FOURNIER PU-PH

✉ pierre-edouard.fournier@ap-hm.fr

📞 33+ 04 13 73 24 31

Principal Investigator

François CREMIEUX

STUDY DIRECTOR

ASSISTANCE PUBLIQUE HOPITAUX D EMARSEILLE

Frequently Asked Questions

Who can join the NCT06485895 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying TUBERCULOSIS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06485895 currently recruiting?

Yes, NCT06485895 is actively recruiting participants. Contact the research team at pierre-edouard.fournier@ap-hm.fr for enrollment information.

Where is the NCT06485895 trial being conducted?

This trial is being conducted at Marseille, France.

Who is sponsoring the NCT06485895 clinical trial?

NCT06485895 is sponsored by Assistance Publique Hopitaux De Marseille. The principal investigator is François CREMIEUX at ASSISTANCE PUBLIQUE HOPITAUX D EMARSEILLE. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology